In Vitro and in Vivo Evaluation of Osteoporosis Therapeutic Peptide PTH 1−34 Loaded PEGylated Chitosan Nanoparticles

Narayanan, Deepa, Anitha, A., Jayakumar, R. and Chennazhi, K. P. (2013) In Vitro and in Vivo Evaluation of Osteoporosis Therapeutic Peptide PTH 1−34 Loaded PEGylated Chitosan Nanoparticles. Molecular Pharmaceutics, 10 11: 4159-4167. doi:10.1021/mp400184v

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
S12_PhD_.pdf Full text (open access) application/pdf 1.81MB 142

Author Narayanan, Deepa
Anitha, A.
Jayakumar, R.
Chennazhi, K. P.
Title In Vitro and in Vivo Evaluation of Osteoporosis Therapeutic Peptide PTH 1−34 Loaded PEGylated Chitosan Nanoparticles
Journal name Molecular Pharmaceutics   Check publisher's open access policy
ISSN 1543-8384
1543-8392
Publication date 2013-09-05
Year available 2013
Sub-type Article (original research)
DOI 10.1021/mp400184v
Open Access Status File (Author Post-print)
Volume 10
Issue 11
Start page 4159
End page 4167
Total pages 9
Place of publication Washington, DC United States
Publisher American Chemical Society
Collection year 2013
Language eng
Formatted abstract
Oral formulation of human parathyroid hormone 1–34 (PTH 1–34) is an alternative patient compliant route in treating osteoporosis. PTH 1–34 loaded chitosan nanoparticles were PEGylated (PEG-CS-PTH NPs) and characterized by DLS, SEM, TEM and FTIR. PEG-CS-PTH NP aggregates of 200–250 nm which in turn comprised 20 nm individual nanoparticles were observed in SEM and TEM images respectively. The PEG-CS-PTH NP with 40% encapsulation efficiency was subjected to an in vitro release in simulated rat body fluids. PEG-CS-PTH NP treated human primary osteoblast cells, upon PTH 1–34 receptor activation, produced second messenger-cAMP, which downstream stimulated intracellular calcium uptake, production of bone specific alkaline phosphatase, osteocalcin etc., which substantiates the anabolic effect of the peptide. PEG-CS-PTH NPs showed an oral bioavailability of 100–160 pg/mL PTH 1–34 throughout 48 h, which is remarkable compared to the bare PTH 1–34 and CS-PTH NPs. The NIR image of gastrointestinal transit of ICG conjugated PEG-CS-PTH NPs supports this significant finding.
Keyword PEGylated chitosan nanoparticle
PTH 134
Improved half life
Oral peptide delivery
Osteoporosis
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Chemistry and Molecular Biosciences
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 10 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 10 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 12 Feb 2015, 12:11:54 EST by Anitha Sudheesh Kumar on behalf of School of Chemistry & Molecular Biosciences